https://www.selleckchem.com/EGFR(HER).html
Allogeneic haematopoietic stem cell transplantation (ALLO-HSCT) is a potentially curative approach to treat β-thalassemia major (β-TM). To assess the quality of life (QOL) of patients with β-TM after ALLO-HSCT, we searched PubMed, Embase, Web of Science, and Medline for articles on the quality of life (QOL) of patients with β-TM from 1 Feb 2020 to 31 Mar 2020. Our review revealed that the QOL of patients with β-TM after ALLO-HSCT from a sibling donor is higher than that of patients that received blood infusion and iron-chelating therapy. Survi
Like
Comment
Share
